Moderna/Merck partnership and its potential in personalised cancer therapies are good opportunities for long-term investors.

When compared to the broader market, Verastem Oncology has shown exceptional performance. The company’s stock has surged 30.57% year-to-date, a stark contrast to the S&P 500’s meager performance of -0 ...

Shares of Verastem surged after the company's new cancer treatment got priority review from regulators. The stock was up 46% at $5.37 on Tuesday. Shares are still down 35% since the start of the year.

Future Prospects: The future of the Vietnam platinum-based cancer drug market is promising. As cancer incidence continues to rise and as oncology research progresses, the demand for these drugs is ...

The global market for Gynecological Cancer Drugs was estimated at US$16.9 Billion in 2023 and is projected to reach US$24.0 Billion by 2030, growing at a CAGR of 5.1% from 2023 to 2030. This ...

Three years ago, my sister asked me what type of tree I wanted as a Christmas present. This wasn’t a simple question, like ...

Recent health news highlights major developments in the pharmaceutical industry, covering GSK's progress in ovarian cancer ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...

(Alliance News) - GSK PLC on Friday said a trial of two ovarian cancer treatments met its primary endpoint but did not meet a key secondary target. The First-Engot-OV44 phase III trial evaluated ...

(Sharecast News) - GSK has announced positive results from a phase III trial of its ovarian cancer treatment, which met its primary endpoint of progression free survival. Headline results from the ...

Treatment for lung cancer varies according to age, type of cancer, extent of disease, tolerance to medication and patient preference. Treatment options include a combination of surgery, radiation, ...